The oncogenic role, regulatory mechanism, and clinical significance of lncRNA HIF1A-AS2 in multiple human cancers Authors: Lei Luo, Juan Zhang, Tingting Yu, Wenqian Tang, Jin Dong, Fan Yang Published: 2026 ABSTRACT AbstractLong non-coding RNAs (lncRNAs) are RNA molecules transcribed over 200 nucleotides in length. Although they do not encode proteins, many studies have shown that they have a dramatic involvement in human cancer by various mechanisms. Hypoxia inducible factor 1α-antisense RNA 2 (HIF1A-AS2) is a lncRNA recently described to map on human chromosome 14q23.2, whose aberrant expression has been observed in many tumor types and whose up-regulation results in poor patient clinical prognosis. Experimental studies demonstrate that HIF1A-AS2 is involved in a wide range of biological processes, including cell proliferation, invasion, migration, apoptosis, drug resistance and epithelial-mesenchymal transition (EMT). Moreover, this lncRNA promotes cancer malignancy by acting as competing endogenous RNA (ceRNA) or by directly binding to certain proteins. This article comprehensively summarizes the function, molecular mechanisms, and clinical significance of HIF1A-AS2 in malignant tumors, pointing out that HIF1A-AS2 has potential functions as diagnostic markers as well as therapeutic targets.Keywords: Long non-coding RNA, HIF1A-AS2, Cancers, Molecular mechanism, Clinical application Introduction Cancer continues to be the leading cause of disease and death worldwide, affecting human health and the wider society. Cancer statistics according to GLOBOCAN reveal around 20 million new cancer cases and 9.7 million cancer deaths worldwide in 2022 [1]. This condition represents a complex pathological condition that is influenced by many factors such as environmental factors, genetic factors, lifestyle factors and dietary factors [2]. In recent years, notable advances have also been made in cancer therapy with immunotherapy and targeted therapy, and hence survival rate in cancer patients has been improved. Nevertheless, the prognosis for cancer patients remains poor owing to heterogeneity of the tumour, interpatient differences and fundamental limitations of available therapies [3]. Therefore, it is fundamental to understand the complex network around tumor development and to determine reliable biomarkers for the early diagnosis and treatment of tumors. Long non-coding RNAs (lncRNAs) are RNA molecules transcribed over 200 nucleotides in length that are not translated into proteins. Originally, because lncRNAs lacked protein-coding ability, they were regarded as mere chips off the RNA polymerase II production line and as having little biological relevance [4]. However, advances in high-throughput sequencing technologies and transcriptomic studies have shown rich evidence that lncRNAs play important roles in various biological processes such as DNA methylation, histone modification, and the post-transcriptional regulation of RNA [5–7]. Furthermore, lncRNAs modulate biological pathways related to cell proliferation, apoptosis, migration, invasion, drug resistance and immune escape in several types of malignant tumor by binding to macromolecules, such as DNA, RNA, proteins-promoters and inhibitors of tumour growth [8, 9]. Therefore, it is important to understand the complex nature of lncRNAs, their effect on different cancer-related physiological processes and their interaction with other molecules to identify their potential roles in cancer regulation and their possible use in personal medicine. However, current reviews in this field exhibit numerous shortcomings: they are descriptive in nature but lack methodological rigor, fail to conduct cross-cancer comparisons of HIF1A-AS2, provide fragmented mechanistic summaries, and overstate its clinical translational potential. Prior to this study, Liu et al. provided an early overview of HIF1A-AS2 as a potential oncogene, though their focus was primarily on descriptive functional summaries based on limited cancer datasets prior to 2020 [10]. This review stands out in five important ways. It provides the first systematic cross-cancer comparison of HIF1A-AS2 expression patterns, underlying mechanisms, and clinical relevance across 12 cancer types; follows a formal literature search strategy to reduce bias; brings together a unified mechanistic framework involving HIF1A-AS2 as a ceRNA, hypoxia, and driver mutations; offers a critical assessment of the barriers to HIF1A-AS2’s clinical translation; and highlights context-dependent roles of HIF1A-AS2 rather than treating it as a universally oncogenic factor. Covering studies published between 2015 and 2026, this review aims to provide a solid and rigorous foundation for the development of future biomarkers and therapeutic targets related to HIF1A-AS2. Literature retrieval strategy and inclusion criteria As of March 15, 2026, the research team conducted a systematic search of PubMed, Web of Science, and Scopus from database inception to the search date. The search strategy was: (“HIF1A-AS2” OR “HIF1A antisense RNA 2” OR “aHIF”) AND (“cancer” OR “carcinoma” OR “tumor” OR “neoplasm”). Eligible studies were limited to clinical or mechanistic investigations related to human cancers and were required to report quantitative data on expression, prognosis, molecular mechanisms, or drug resistance. Reviews, case reports, and other non-empirical studies without original data were excluded. Two authors independently screened the records, and disagreements were resolved by a third reviewer. Of the 78 records initially identified, 32 studies met the inclusion criteria and were included in the final analysis. Genomic localization and expression profile Thrash-Bingham and Tartof identified lncRNA hypoxia inducible factor 1α-antisense RNA 2 (HIF1A-AS2) in 1999, demonstrating its ability to interact with the 3’-untranslated region (UTR) of hypoxia-inducible factor 1alpha (HIF-1α) in clear cell renal carcinoma [11]. On the basis of information from the NCBI-Gene database (https://www.ncbi.nlm.nih.gov/), HIF1A-AS2 is located on chromosome 14q23.2 and has one transcript and one exon, totaling 2051 nucleotides (Fig. 1). Also with the online GEPIA2 website, we found that HIF1A-AS2 was differentially expressed in kidney renal clear cell carcinoma (KIRC) (Fig. 2). As a key oncogene, HIF1A-AS2 regulates the progression of tumor advancement to control different characteristics of tumor cells, such as cell cycle, proliferation, migration, invasion, epithelial to mesenchymal transition (EMT) and drug resistance. Furthermore, the expression of HIF1A-AS2 in different tumor tissues and cells is associated with clinicopathological status, such as the tumor size, differentiation grade, TNM staging and lymph node metastasis. Increased expression of HIF1A-AS2 has also been shown to be associated with a poor prognosis for cancer patients. Schematic diagram of the formation of lncRNA HIF1A-AS2. HIF1A-AS2 was located on the human chromosome 14q23.2, with one transcript and one exon (extracted from the NCBI-Gene database) The expression profile of HIF1A-AS2 in various cancer tissues and normal tissues was obtained according to the GEPIA database analysis However, the present study found that current evidence on HIF1A-AS2 expression is derived largely from retrospective analyses of TCGA data, while validation in independent prospective cohorts remains lacking. In addition, these data do not adequately capture the heterogeneity of HIF1A-AS2 expression within the hypoxic tumor microenvironment, such as spatial differences in HIF-1α-dependent regulatory regions. The functional role of HIF1A-AS2 in different cancers Several studies have shown a robust correlation between elevated HIF1A-AS2 levels and unfavorable outcomes in various cancer types (Table 1). The functions and underlying mechanisms of HIF1A-AS2 in cancer are listed in Tables 2 and 3. Table 1Expression and clinical significance of HIF1A-AS2 in various cancersTumor typeSample sizeExpressionSignificant clinicalfeaturesPrognostic implication of HIF1A-AS2 up-regulationPropertyReferenceGastric cancer83UpregulationTumor invasion, lymph node metastasis, higher TNM stage and overall survivalPoorOncogene14Gastric cancer80UpregulationTumor size, H. pylori infection, TNM stage, and lymph node metastasisPoorOncogene15Gastric cancer50UpregulationTumor size, TNM stage, lymph node metastasis and overall survivalPoorOncogene16Colorectal cancer92UpregulationTNM stage and overall survivalPoorOncogene22Colorectal cancer106UpregulationDisease-free survival, overall survival, pathological stagePoorOncogene24Bladder cancer44UpregulationHistological grade, tumor invasion depth and TNM stagePoorOncogene31Cervical cancer20UpregulationClinical stage and overall survivalPoorOncogene35Cervical cancer20Upregulation-PoorOncogene37Non-Small Cell Lung Cancer47UpregulationSurvival ratePoorOncogene42Lung adenocarcinoma129UpregulationDisease-free survival and overall survivalPoorOncogene43Renal cell carcinoma42Upregulation-PoorOncogene48Renal cell carcinoma83UpregulationTumor size, differentiation, and TNMstagesPoorOncogene49Triple-negative breast cancer86UpregulationLymph node metastasis, distantmetastasis, and unfavorable histological gradePoorOncogene53Triple-negative breast cancer10Upregulation-PoorOncogene57Osteosarcoma30UpregulationOverall survivalPoorOncogene59 Expression and clinical significance of HIF1A-AS2 in various cancers Tumor size, differentiation, and TNM stages Lymph node metastasis, distant metastasis, and unfavorable histological grade Table 2Biological role of HIF1A-AS2 in diverse tumorsCancer typeCell linesExpressionRelated biological activitiesTarget genes/pathwayRoleReferenceGastric cancerMGC−803, SGC−7901,BGC−823 and AGSUpregulationProliferation↑-Oncogene14Gastric cancerSNU−5, HGC−27, MKN45 and AGSUpregulationProliferation↑, Metastasis↑HIF1A-AS2/miR−429/PD-L1Oncogene16Colorectal cancerSW620,DLD−1, HT−29 and HCT116UpregulationProliferation↑,Invasion↑, epithelial-mesenchymal transition↑HIF1A-AS2/miR−129−5p/ DNMT3AOncogene22Colorectal cancerHCT15, HCT8, DLD1, RKO, SW480, HCT116, SW620, LoVo, HT29, Caco2, COLO205 andSW1116UpregulationProliferation↑, metastasis↑, aerobic glycolysis↑HIF1A-AS2/miR−141−3p/FOXC1Oncogene24Head and Neck CancerMCF7 and MDA-MB231UpregulationApoptosis↓HIF1A-AS2/NBR1/MHC-IOncogene26Bladder cancer5637 and T24UpregulationProliferation↑, migration↑, apoptosis↓-Oncogene31Bladder cancerT24, 5637 and SW780UpregulationApoptosis↓, cisplatin resistance↑HIF1A-AS2/HMGA1-p53Oncogene32Cervical cancerCaSki, SiHa and HeLaUpregulationProliferation↑, migration↑, invasion↑, apoptosis↓HIF1A-AS2/P53/caspase9/caspase3Oncogene35Cervical cancerHeLa, SiHa and CaSkiUpregulationProliferation↑, invasion↑, apoptosis↓HIF1A/AS2/miR−34b−5pOncogene37Non-Small Cell Lung CancerBEAS−2BUpregulationProliferation↑, migration↑, invasion↑, apoptosis↓HIF1A-AS2/miR−153−5p/S100A14Oncogene42Lung adenocarcinomaH1299, H460, A549, H1975, CALU1 and CALU6UpregulationProliferation↑, metastasis↑HIF1A-AS2/DHX9/MYCOncogene44Lung adenocarcinomaPC9, A549, HCC827 and H1975UpregulationOsimertinib resistance↑HIF1A-AS2/miR−146b−5p/IL−6/STAT3Oncogene45Small cell lung cancerH69AR and H69UpregulationAutophagy↑-Oncogene46Renal cell carcinomaACHN, OSRC−2, 786-O and Caki−1UpregulationProliferation↑, migration↑, invasion↑, apoptosis↓HIF1A-AS2/miR−130a−5p/ERBB2Oncogene48Renal cell carcinoma786-O, ACHN, OS-RC−2 and 293TUpregulationProliferation↑, migration↑, apoptosis↓HIF1A-AS2/miR−30a−5p/SOX4Oncogene49Triple-negative breast cancerMCF−10 A, DU4475, HCC1806 and MDA-MB−468UpregulationMigration↑, invasion↑-Oncogene53Triple-negative breast cancerMDA-MB−453 and MDA-MB−474UpregulationProliferation↑, metastasis↑, invasion↑, paclitaxel resistance↑HIF1A-AS2/MRPS23Oncogene57OsteosarcomaU2OS, SoSP-M, SaOS-2 and MG−63UpregulationProliferation↑, cell cycleprogression↑, invasion↑HIF1A-AS2/miR−129−5pOncogene59Gastrointestinal stromal tumorGIST-T1 and GIST882UpregulationAutophagy↑, imatinib resistance↑-Oncogene61Glioblastoma multiformeG2, G6, G33, G34, G35, G44, G62, G88, G146, G157 and G91UpregulationProliferation↑, survival↑, self-renewal capacity↑HIF1A-AS2/IGF2BP2-DHX9/HMGA1Oncogene63↑ : ↑ means promoting; ↓ : ↓ means inhibiting Biological role of HIF1A-AS2 in diverse tumors MGC−803, SGC−7901, BGC−823 and AGS Proliferation↑, Invasion↑, epithelial-mesenchymal transition↑ HCT15, HCT8, DLD1, RKO, SW480, HCT116, SW620, LoVo, HT29, Caco2, COLO205 and SW1116 HIF1A-AS2/miR−130a−5p/ ERBB2 MCF−10 A, DU4475, HCC1806 and MDA- MB−468 U2OS, SoSP-M, SaOS- 2 and MG−63 Proliferation↑, cell cycle progression↑, invasion↑ ↑ : ↑ means promoting; ↓ : ↓ means inhibiting Table 3Effects of HIF1A-AS2 on growth and metastasis of cancer xenograftsCancer typeAnimal modelsFunctionReferenceGastric cancer4−6-week-old BALB/c nude mice↓↓HIF1A-AS2: ↓tumor growth16Colorectal cancer4-week-old BALB/c nude mice↓↓HIF1A-AS2: ↓tumor growth, ↓tumor weight, ↓Ki−67 and ↑E-cadherin24Cervical cancer4-week-old BALB/c nude mice↓↓HIF1A-AS2: ↓tumor growth, ↓tumor weight and ↓ Ki−6735Lung adenocarcinoma4−6-week-old female NOD/SCID Gamma mice↑↑HIF1A-AS2: ↑tumor growth, ↑tumor weight44Lung adenocarcinoma7-week-old female BALB/c nude mice↓↓HIF1A-AS2: ↓tumor growth, ↓tumor weight, ↓Ki−67, ↓IL−6 and ↓p-STAT345Renal cell carcinoma5-week-old male BALB/c nude mice↓↓HIF1A-AS2: ↓tumor growth and ↓SOX449Glioblastoma multiforme6−8-week-old female athymic nude mice↓↓HIF1A-AS2: ↓tumor growth, ↑prolonged survival63↑↑ HIF1A-AS2: ↑↑ means HIF1A-AS2 overexpression; ↑: ↑ means promoting. ↓↓ HIF1A-AS2: ↓↓ means HIF1A-AS2 knockdown or knockout; ↓: ↓ means inhibiting Effects of HIF1A-AS2 on growth and metastasis of cancer xenografts ↑↑ HIF1A-AS2: ↑↑ means HIF1A-AS2 overexpression; ↑: ↑ means promoting. ↓↓ HIF1A-AS2: ↓↓ means HIF1A-AS2 knockdown or knockout; ↓: ↓ means inhibiting Gastric cancer Gastric cancer (GC) is a malignant epithelial tumor arising in the stomach, which ranks at fifth place of incidence and third place of death worldwide [12]. Most patients with GC are at an advanced stage of the disease because of the lack of early symptoms and the low rate of screening, and usually present with invasion or metastases. Despite remarkable advances in diagnostic methods and treatment for GC, their prognosis remains dismal for GC patients, especially for those with unresectable advanced or recurrent diseases, whose lives are extremely short [13]. Hence, Identification of early diagnostic markers and therapeutic targets for GC is crucial. HIF1A-AS2 expression is markedly elevated in GC tissue compared to adjacent tissue, and its overexpression is closely associated with tumor invasion, lymph node metastasis, and advanced TNM stage in GC patients [14]. Kaplan-Meier analysis showed that the overall survival (OS) rate of patients with high HIF1A-AS2 expression level was much shorter than that with low HIF1A-AS2 expression, with 5-year median OS duration of 24 months and 45 months, respectively (P < 0.01). These results suggest that the level of HIF1A-AS2 expression may also be a predictor of the OS in GC [14]. Helicobacter pylori is a major risk factor for GC and is listed as a group 1 carcinogen by WHO. By browsing the GSE224056 database, we found that HIF1A-AS2 is a differentially expressed lncRNA in GC cell lines infected with Helicobacter pylori. Along with the increased levels of HIF1A-AS2 found in patients with larger tumours, Helicobacter pylori infection, stage III or IV cancer and lymph node metastasis. These findings indicate that HIF1A-AS2 is associated with Helicobacter pylori related GC, and may be used as a marker for the diagnosis and prognosis of HIF1A-AS2 [15]. The silencing of HIF1A-AS2 hampered the proliferation, migration, and invasion of GC cells while also inhibiting tumor growth. Mechanistically, HIF1A-AS2 is found to indirectly influence PD-L1 expression through the inhibition of miR-429, thus facilitating the proliferation and metastasis of GC cells [16]. Recent studies indicate a strong link between lysyl oxidase (LOX) and various processes such as tumor cell proliferation, migration, invasion, and metastasis [17]. Bioinformatics showed that the expression of LOX was dramatically increased in GC tissues. Furthermore, HIF1A-AS2 also acts as a competing endogenous RNA (ceRNA) for miR-429 and regulates LOX by influencing miR-429. This regulatory pathway contributes to the polarization of M2 macrophages, facilitates immune escape in tumors, and increases the resistance of cancer cells to chemotherapy, resulting in a worse prognosis for patients with GC [18]. In studies of GC, the current evidence on HIF1A-AS2 remains limited. All included cohorts had relatively small sample sizes (n < 100) and lacked multicenter validation, which restricts the generalizability and external validity of the findings. At the mechanistic level, current explanations of HIF1A-AS2 function are largely based on inferred ceRNA networks, while rescue experiments targeting endogenous miRNA interactions are still needed to further confirm these regulatory relationships. Summarizing, HIF1A-AS2 is a growth promoter for GC and has potential as a novel diagnostic and prognostic factor for people diagnosed with GC. However, the underlying molecular mechanisms need to be further studied experimentally. Colorectal cancer The rate of diagnosis for colorectal cancer (CRC) is relatively high, largely due to the prevalent use of colonoscopy. Nonetheless, colonoscopy remains an invasive procedure. Moreover, the rising incidence of CRC among individuals under 50 years of age is concerning, particularly for colorectal and left-sided colon cancers [19]. Research indicates that lncRNAs are vital in both the onset and progression of CRC, with examples including lncRNA SNHG15 and lncRNA DANCR [20, 21]. Notably, the role of HIF1A-AS2 as an oncogene in CRC has also been established. Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) data indicated that expression of HIF1A-AS2 was increased in the tissues and cells of CRC compared with normal tissues and cells, and overexpression of HIF1A-AS2 correlated with poor outcomes of CRC patients. Bioinformatics studies and dual luciferase reporter gene assay confirmed that HIF1A-AS2 serves as a ceRNA to competitively bind miR-129-5p and upregulate the expression of DNA Methyltransferase 3 Alpha (DNMT3A), thereby facilitating the malignant progression and EMT of CRC [22]. Forkhead box C1 (FOXC1) is an essential oncogene that promotes the development of tumour for various cancers [23]. Both transwell invasion and cell migration assays showed that silencing HIF1A-AS2 suppressed the proliferation, migration and invasion of CRC cells. Overlying mechanism is HIF1A-AS2 mediated increase in FOXC1 by sequestration of miR-141-3p, which promotes CRC progression [24]. This indicates that the mechanistic evidence for HIF1A-AS2 remains incomplete. Most available findings rely on luciferase reporter assays to support its role in ceRNA regulation, but sufficient endogenous rescue experiments are lacking. As a result, these regulatory relationships have not been fully confirmed in the native cellular context. In addition, ceRNA activity in vivo is influenced by miRNA abundance, and whether HIF1A-AS2 can exert an effective “sponge effect” may depend on a certain expression threshold. Head and neck cancer Head and neck cancer (HNC) is a highly aggressive disease, with about 600 000 new cases diagnosed each year [25]. Although tremendous efforts have been made to treat HNC, outcomes remain poor. Liao et al. described the key role of HIF1A-AS2 in HNC progression [26]. The presence of intratumoral hypoxia is pivotal in fostering tumor development, aiding in angiogenesis and tumor cell invasion while creating an immunosuppressive microenvironment that supports tumor growth [27]. Given the relatively large tumor size and hypoxic conditions seen in HNC, HNC cells often show resistance to immunotherapy and are more likely to recur. In hypoxic HNC cells and HNC exosomes, HIF1A-AS2 expression is upregulated. Also in tissues from patients with HNC, levels of HIF1A-AS2 were positively correlated with the hypoxia marker HIF-1α and strongly associated with advanced clinical stages. As HIF1A-AS2 promotes the binding of the autophagic cargo receptor neighbor of BRCA1 gene 1 (NBR1) to the major histocompatibility complex class I (MHC-I), the MHC-I protein stability is attenuated and more autophagic degradation of MHC-I was observed in hypoxic HNC cells. Consequently, it contributes to the development of HNC [26]. The areca nut is a major carcinogenic risk factor for HNC in South-east Asia, but the mechanism is not known. By linking the findings from in vitro cell experiments to the TCGA-HNC clinical database analysis, HIF1A-AS2 was markedly upregulated in HNC cells induced by betel nut and that HIF1A-AS2 is one of carcinogenic lncRNAs [28]. Bladder cancer As the predominant solid malignant tumor of the urinary system globally, bladder cancer (BLCA) poses a significant economic burden and a high rate of morbidity for patients, frequently culminating in the death of those with advanced disease [29]. In BLCA tissues and cells, HIF1A-AS2 overexpressed, and it exists in both clinicopathological grade and TNM stage with positive expression in BLCA tissues and cells. Of note, silencing of HIF1A-AS2 suppressed cell migration and induced cell apoptosis in BLCA T24 and 5637 cells. Conversely, the overexpression of HIF1A-AS2 enhances cell proliferation, migration, and resistance to apoptosis in BLCA cells [30]. Cisplatin is a key drug employed for chemotherapy of BLCA, but resistance to cisplatin is one of the major obstacles for successful therapy. In cisplatin-treated BLCA cells and tissues that are resistant to cisplatin, HIF1A-AS2 expression is notably elevated, suggesting that it may facilitate chemoresistance in BLCA by suppressing apoptosis in cells. Further investigations revealed that high mobility group A1 (HMGA1) acts as a downstream target of HIF1A-AS2, whereby HIF1A-AS2 augments the cisplatin resistance of BLCA through the upregulation of HMGA1 expression, which in turn inhibits the transcriptional activity of P53 family proteins [31]. Hence, HIF1A-AS2 may serve as a lncRNA biomarker for treatment of BLCA. Cervical cancer Cervical cancer (CC) is the fourth most commonly diagnosed malignant tumor in women worldwide, with approximately 600 000 new CC cases and 340 000 CC-related deaths worldwide in 2022 [32]. Although the incidence of CC has decreased significantly in the past 30 years, it is still a global public health problem. Dysregulation of lncRNAs in CC may potentially accelerate its progression. Tumor invasion and migration are important malignant biological characteristics, and silencing HIF1A-AS2 can inhibit the proliferation, invasion and migration of CC cells [33]. High-throughput microarray analysis showed that the expression of HIF1A-AS2 was significantly up-regulated in HPV-positive CC tissues. Further RT-qPCR analysis showed that the expression of HIF1A-AS2 in 20 CC tissues was significantly higher than that in 9 normal cervical epithelial tissues, and high HIF1A-AS2 expression was significantly correlated with poor survival rate of patients [34]. Studies have shown that HPV oncoprotein E6 is directly related to the malignant progression of CC [35]. Knockdown of HPV-16 E6 resulted in impaired HIF1A-AS2 expression, whereas overexpression of HPV-16 E6 significantly enhanced HIF1A-AS2 expression, indicating that HIF1A-AS2 is affected by HPV-16 E6. E6 can regulate cell apoptosis through P53, and HIF1A-AS2 overexpression can reverse the increase of P53 and apoptosis-related factors (caspase9 and caspase3) levels in HPV-16 E6 knockdown CC cells, thus playing a carcinogenic role in CC [34]. Liu et al. also demonstrated that knockdown of HIF1A-AS2 significantly inhibited the proliferation and invasion of CC cells while inducing apoptosis. Jun acts as a transcription factor to activate the expression of HIF1A-AS2, and HIF1A-AS2 acts as a molecular sponge targeting radixin (RDX) of miR-34b-5p to play a carcinogenic role in CC [36]. In CC, the role of HIF1A-AS2 appears to be strongly virus-associated and context-specific. Significant upregulation of HIF1A-AS2 has mainly been observed in HPV-positive cervical cancer patients, whereas its biological relevance in HPV-negative settings remains insufficiently supported. Therefore, the functional interpretation of HIF1A-AS2 in cervical cancer should take HPV infection status into account. Lung cancer Lung cancer is the leading cause of cancer-related deaths worldwide, claiming over 1.8 million lives annually and posing a serious threat to public health [1]. Lung cancer is usually divided into two types: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), with NSCLC accounting for approximately 85% of all cases [37, 38]. The treatment of NSCLC as its major histological subtype has made important progress in the past two decades, but the 5-year OS rate remains poor, especially in metastatic disease [39]. Therefore, further studies are needed to improve the prognosis of NSCLC. It has been reported that the expression of HIF1A-AS2 in NSCLC tissues and cells is significantly higher than that in adjacent tissues and normal lung epithelial cells, and the expression is increased in advanced NSCLC tissues, indicating that the high expression of HIF1A-AS2 is related to poor prognosis [40]. Kristen rat sarcoma viral oncogene (KRAS) belongs to a genotype of NSCLC, and its genotype is closely related to the occurrence and development of NSCLC [41]. Yang et al. found that HIF1A-AS2 is a KRAS-responsive lncRNA that is highly expressed in NSCLC and associated with poor prognosis of patients. The mechanism is that HIF1A-AS2 recruits the RNA-binding protein DExH-Box helicase 9 (DHX9) to the myelocytomatosis oncogene (MYC) promoter region, epigenetically activates MYC transcription, and stimulates the expression of MYC and its target genes. On the other hand, activated MYC is in turn able to transcriptionally activate HIF1A-AS2 expression. Meanwhile, KRAS promotes HIF1A-As2 expression by inducing MYC, forming a HIF1A-AS2-MYc-KRAS triple regulatory network, thereby promoting NSCLC proliferation and tumor metastasis [42]. Lung adenocarcinoma (LUAD) is one of the major subtypes of NSCLC. The epidermal growth factor receptor tyrosine kinase inhibitor osimertinib has significantly improved the prognosis of LAUD patients. However, the development of acquired resistance limits treatment outcomes. HIF1A-AS2 acts as a ceRNA sponge to adsorb miR-146b-5p and relieve the inhibition of downstream protein interleukin-6 (IL-6), thereby activating IL-6/STAT3 signaling pathway, promoting the proliferation, migration and tumorigenesis of LUAD cells, and enhancing the resistance of LUAD cells to osimertinib. This study suggests that miR-146b-5p/IL-6/STAT3 axis may be a potential therapeutic target for improving LUAD resistance to osimertinib [43]. Similarly, the expression of HIF1A-AS2 is also significantly increased in azithromycin resistant SCLC. Knockdown of HIF1A-AS2 can improve the sensitivity of SCLC cells to azithromycin, reduce the level of autophagy, and increase the apoptosis rate [44]. These studies indicate that HIF1A-AS2 is a key biomolecator in lung cancer progression and can potentially be targeted in the development of novel therapeutic approaches, but the mechanisms need to be further elucidated. Renal carcinoma Renal cell carcinoma (RCC) is a tumor with a very high mortality rate and sparse symptoms in its early stages, which leads to late clinical diagnosis and an adverse prognosis, and a large failure rate with chemotherapy [45]. There is an urgent need to generate novel and effective biomarkers for early diagnosis and efficacy monitoring to improve treatment efficacy of patients with RCC. HIF1A-AS2, a novel lncRNA, participates in the initiation and progression of RCC. Furthermore, the HIF1A-AS2 expression levels were remarkably elevated in the RCC tissues and cell lines. Down-regulation of HIF1A-AS2 expression decreased proliferation, migration and invasion in the RCC cells and increased apoptosis. Additionally, a rescue experiment shows that overexpression of HIF1A-AS2 resulted in down-regulation of miR-130a-5p, implying that HIF1A-AS2 behaves as an oncogene via suppression of miR-130a-5p [46]. Furthermore, another investigation highlighted that the elevated levels of HIF1A-AS2 are significantly associated with tumor size, TNM classification, and the degree of differentiation. Mechanistically, the increase in HIF1A-AS2 expression diminishes the levels of miR-30a-5p, which in turn enhances the expression of SRY-box transcription factor 4 (SOX4) and WNT signaling pathways at the post-transcriptional level, thus exacerbating the malignant characteristics of RCC [47]. In summary, HIF1A-AS2, as a ceRNA involved in two pathways, exerts carcinogenic effects and serves as a therapeutic and prognostic biomarker for RCC. Breast cancer Breast cancer (BC) is one of the most common cancers worldwide and the second leading cause of cancer-related deaths in women, with approximately 2.26 million people diagnosed with BC each year in the United States [48]. Early diagnosis and treatment are the key to improve the prognosis of BC. Previous studies have shown that a variety of lncrnas are involved in the occurrence and development of BC [49]. Triple-negative breast cancer (TNBC), as one of the subtypes of BC, is considered to be the most aggressive and fatal type of BC. Multiple studies have shown that HIF1A-AS2 plays a key role in the diagnosis and prognosis of TNBC. The expression level of HIF1A-AS2 in plasma of TNBC patients was significantly higher than that of non-TNBC patients, and was positively correlated with the level of tumor tissue, indicating that the level of HIF1A-AS2 in plasma can reflect the expression in tissues [50]. ROC curve analysis showed that HIF1A-AS2 showed excellent diagnostic performance when combined with other two lncRNAs (ANRIL and UCA1), with an AUC of 0.934, a sensitivity of 76.0%, and a specificity of 97.1%, which provided an important molecular marker for the non-invasive diagnosis of TNBC [51]. High expression of HIF1A-AS2 is related to lymph node metastasis, distant metastasis and poor histological grade in TNBC patients, and the OS of TNBC patients with high expression of HIF1A-AS2 is shorter than that of patients with low expression of HIF1A-AS2 [52]. Through the analysis of 2803 TNBC patients and 27 different literatures, Zhang et al. also found that the expression of HIF1A-AS2 increased in TNBC, and the high expression was significantly related to the poor prognosis of patients [53]. Paclitaxel chemotherapy is the standard treatment for TNBC, and its combination with other chemotherapy drugs can effectively inhibit tumor progression and benefit patients. However, drug resistance remains a major challenge [52]. HIF1A-AS2 can promote the proliferation and invasion of TNBC cells and lead to paclitaxel resistance [54]. Transcriptome sequencing analysis identified mitochondrial ribosomal protein S23 (MRPS23) as a downstream target protein regulated by HIF1A-AS2, and the knockdown of HIF1A-AS2 reduced the expression of MRPS23 in TNBC cells, thereby affecting the proliferation, migration and invasion of TNBC cells and increasing the sensitivity to paclitaxel [55]. Other types of cancer Besides the previously mentioned tumors, HIF1A-AS2 has also demonstrated oncogenic properties in a range of other cancers, including ovarian cancer (OC), gastrointestinal stromal tumors (GIST), osteosarcoma, and glioblastoma multiforme (GBM). Osteosarcoma constitutes the primary cause of cancer-related fatalities in children and adolescents and is recognized as the most prevalent primary malignant bone tumor [56]. Recent research indicates that HIF1A-AS2 is significantly overexpressed in tissues and cells of osteosarcoma [57]. Moreover, osteosarcoma patients with high HIF1A-AS2 expression in the primary tumor had a median survival time of 50 months, which was shorter than that of patients with low HIF1A-AS2 expression (92 months). HIF1A-AS2 promotes the proliferation, cell cycle progression and invasion ability of osteosarcoma cells by acting as a sponge for miR-129-5p [57]. In various solid tumors, rapid proliferation of tumor cells leads to hypoxia within the tumor. HIF-1α is the main mediator of hypoxia response, which promotes cancer progression and chemotherapy resistance by activating downstream gene transcription [58]. Microarray analysis showed that HIF1A-AS2 expression was up-regulated in imatinib-resistant GIST samples. HIF-1α positively regulates the expression of HIF1A-AS2 in hypoxic environment, and the knockdown of HIF1A-AS2 can increase the sensitivity of GIST cells to imatinib and promote cell apoptosis, while inhibiting the imatinib-induced autophagy [59]. Similarly, in OC, HIF-1α can increase the expression of HIF1A-AS2 under continuous hypoxia, leading to the degradation of HIF-1α mRNA and ultimately reducing the expression of HIF-1α protein. Meanwhile, it also makes OC cells sensitive to olaparib, carboplatin and cisplatin, providing a new effective strategy for the treatment of OC [60]. HIF1A-AS2 expression was up-regulated in GBM, and in vivo experiments confirmed that knockdown of HIF1A-AS2 significantly delayed the growth of GBM-derived intracranial xenograft tumors and prolonged the survival of mice [61, 62]. Overall, HIF1A-AS2 shows a relatively consistent pattern of upregulation across multiple tumor types. Current evidence indicates increased HIF1A-AS2 expression in 12 cancers, with the most pronounced fold changes observed in lung adenocarcinoma, TNBC, and head and NSCC. By contrast, the evidence in RCC and BLCA appears weaker, largely because of small cohort sizes. Mechanistically, HIF1A-AS2 is most commonly described as acting through ceRNA networks involving miR-429, miR-129-5p, miR-141-3p, and miR-146b-5p. HIF1A-AS2 activity may also depend on specific driver events, such as HPV infection in CC and KRAS mutation in NSCLC. Regarding treatment resistance, HIF1A-AS2 has been associated with cisplatin resistance in BLCA, osimertinib resistance in lung adenocarcinoma, paclitaxel resistance in TNBC, and imatinib resistance in gastrointestinal stromal tumors. Importantly, HIF1A-AS2 should not be regarded simply as a pan-cancer oncogene; its function is highly context dependent and is shaped by hypoxic status, driver oncogenes, the immune microenvironment, and tissue origin. In hypoxic tumors such as HNC, glioblastoma, and GISTs, HIF1A-AS2 is better viewed as a hypoxia-responsive effector rather than a universal driver. In persistently hypoxic OC. Potential clinical applications of HIF1A-AS2 In recent years, advancements in cancer research lead to promising progress of tumour treatment, providing better survival chances for cancer patients. Despite these advancements, several persistent challenges remain within the field. Key issues include the scarcity of early diagnostic markers, the complexities of tumor metastasis, the challenges posed by chemotherapy resistance, and the frequent recurrence of tumors [63]. Addressing these problems is important because the development and identification of early markers of diagnosis and therapeutic targets can benefit patients substantially, leading to earlier diagnosis and better treatment options. Extensive studies have shown that lncRNAs exist ubiquitously in human cancers tissues, blood and various other human tissues. Their ubiquitous expression has even drawn their attention as a promising area of research for cancer diagnosis, prognosis and therapeutic cancer biomarkers. Thanks to the unique detectability and specificity of lncRNAs, they are also a promising target for researchers whose aim is to improve cancer care [64, 65]. Similarly, HIF1A-AS2 exhibits differential expression in a variety of cancers and shows great promise as a biomarker for future diagnostic, therapeutic, and prognostic purposes (Fig. 3). The significance of HIF1A-AS2 in human cancer is evident through its abnormal expression in tumor-derived samples from various sources. HIF1A-AS2 dysregulation affects cancer cell proliferation, migration and invasion. Diagnostic accuracy is demonstrated by ROC curve analysis, and its expression correlates with clinical parameters like tumor stage, metastasis, and recurrence. Kaplan-Meier survival analysis supports risk stratification based on HIF1A-AS2 levels. Continuous monitoring of HIF1A-AS2 aids in assessing tumor severity and progression. Functional assays using cancer cell lines and in vivo models highlight the role of HIF1A-AS2 on malignant characteristics, emphasizing its potential as a therapeutic target As a diagnostic marker More recent studies have found that HIF1A-AS2 is notably overexpressed in different kinds of malignant tumors tissues and cell lines when compared with normal tissues and cells, which provides its value as an auxiliary diagnostic marker for cancer [30, 34, 40]. Using Pearson correlation analysis, we found that there was a positive correlation between HIF1A-AS2 levels and concentrations of cancer biomarkers such as CEA (carcinoembryonic antigen), CA 72 − 4 (cancer antigen 72 − 4) and CA 19 − 9 (cancer antigen 19 − 9) (P < 0.001), and suggest a positive association of the levels of serum biomarkers with HIF1A-AS2 expression in GC patients [15]. Meanwhile, the ROC curve was used to analyse the diagnostic meaning of HIF1A-AS2 in GC patients, and the AUC was 0.759, the specificity was 75% and the sensitivity was 70%, which demonstrates its promising diagnostic value in the context of GC [16]. Most of the recent studies of HIF1A-AS2 stress the tissue and cellular expression profiles. New evidence also suggests higher levels of HIF1A-AS2 in the plasma of TNBC patients. Specifically, the ROC analysis showed that the ability of HIF1A-AS2 alone to distinguish between TNBC and non-TNBC was AUC 0.739. However, HIF1A-AS2 combined with the two lncRNAs (ANRIL and UCA1) significantly improved the diagnostic capacity (AUC = 0.934, sensitivity 76.0%, specificity 97.1%), thus exemplifying its use for non-invasive TNBC diagnosis [52]. Tissue-based studies consistently report upregulation of HIF1A-AS2 in tumors, suggesting possible value as an auxiliary diagnostic marker. For plasma-based detection, the clearest validation so far comes from TNBC: HIF1A-AS2 alone achieved an AUC of 0.739, while a three-lncRNA panel including HIF1A-AS2 increased the AUC to 0.934, indicating that combined biomarkers may outperform a single marker. Nevertheless, several important limitations remain. There is no standardized assay kit, multicenter validation is lacking, and no clinically applicable expression cutoff has been defined. Therefore, the diagnostic value of HIF1A-AS2 still needs to be confirmed in larger, prospective studies with standardized methodologies. As a therapeutic marker Targeted therapy is a type of therapy that targets specific molecular targets in tumor cells, with the focus on finding accurate and beneficial targets, and the hyperspecificity of lncRNAs makes them targets for therapeutic applications [66]. Extensive preclinical studies have demonstrated that knocking down HIF1A-AS2 by RNA interference greatly inhibits proliferation, migration and invasion of tumor cells and induces apoptosis of different tumor cell lines [16, 24, 46]. At present, the inhibition strategy against HIF1A-AS2 only focuses on small interfering RNA, while the research on antisense oligonucleotides is relatively limited, which provides the direction of exploring new targeted therapy. So far, clinical trials targeting HIF1A-AS2 do not exist. However, studies on the function and molecular mechanism of HIF1A-AS2 in a number of tumors have laid a foundation for the clinical treatment of HIF1A-AS2. Many experiments reported that HIF1A-AS2 as an oncogene functioned carcinogenic role for GC, CRC, NSCLC, CC, EC, osteosarcoma, RCC, GIST, OC and GBM. Drug resistance during chemotherapy presents great problems for the treatment of cancer and increasing the sensitivity to chemotherapy is a key point in improving efficacy [67]. Overexpression of HIF1A-AS2 increased the drug resistance of BC cells, and downregulation of HIF1A-AS2 increased the sensitivity of BC cells to chemotherapy drug cisplatin [31]. Similarly, high expression of HIF1A-AS2 in LUAD can enhance the resistance of LUAD cells to osimertinib, this is related to the regulation of miR-146b-5p/IL-6/STAT3 axis [43]. HIF1A-AS2 knockdown significantly decreased tumor growth in xenograft GC mice in GC mouse models [16]. In terms of therapeutic development, HIF1A-AS2 shows potential as an intervention target. Studies using xenograft models have shown that siRNA- or shRNA-mediated silencing of HIF1A-AS2 can inhibit tumor growth, suggesting that it may be a targetable lncRNA. However, the current evidence remains far from clinical translation. Reliable in vivo delivery systems have not yet been established, and systematic safety or toxicity data are lacking. Moreover, no clinical trials have evaluated HIF1A-AS2-targeted therapy to date. Overall, HIF1A-AS2 is better viewed as an early exploratory therapeutic target that requires further evidence regarding delivery strategies, safety assessment, and indication selection. As a prognostic marker Monitoring cancer prognosis is essential for assessing the treatment efficacy of patients and reducing cancer mortality [68]. Increased expression of HIF1A-AS2 has been confirmed to be significantly associated with poor prognosis of cancer, such as OS and advanced clinical features (such as lymph node metastasis and advanced clinical stage). Kaplan-Meier survival analysis showed that the OS of GC patients with high expression of HIF1A-AS2 was significantly shortened, and the median 5-year survival time of the two groups was 24 months and 45 months, respectively. Moreover, the 5-year OS of HIF1A-AS2 was related to clinical factors such as lymph node metastasis, TNM stage, and depth of tumor invasion [14]. HIF1A-AS2 expression is increased in advanced NSCLC tissues, and its high expression is associated with poor prognosis [40]. In LUAD, the disease-free survival (DFS) rates and OS rates of patients with high HIF1A-AS2 expression were significantly lower than those with low HIF1A-AS2 expression, suggesting that HIF1A-AS2 expression is related to the prognosis of LUAD [43]. RT-qPCR analysis showed that HIF1A-AS2 was highly expressed in TNBC, and its high expression was associated with shortened survival time and increased risk of lymph node metastasis and distant metastasis, which can be used as a potential biomarker for prognosis monitoring in TNBC [52]. Another study reviewed and analyzed TNBC-related data, revealing that high expression of HIF1A-AS2 is a high-risk factor for TNBC tumor recurrence [69]. From a prognostic perspective, current studies generally suggest that high HIF1A-AS2 expression is associated with poorer OS and DFS, indicating its potential value for prognostic stratification. However, this conclusion should be interpreted with caution. All available evidence comes from retrospective studies, and none has explicitly followed the REMARK guidelines for study design and reporting. In addition, the included cohorts are generally small, with a median sample size of approximately 80 patients, and external validation is lacking. Therefore, the clinical reliability of HIF1A-AS2 as a prognostic biomarker remains to be confirmed in larger, prospective, and methodologically standardized studies. Molecular mechanisms of HIF1A-AS2 The roles played by HIF1A-AS2 in cancer can be categorized into two types: ceRNA activity and protein interactions. Acting as ceRNAs The ceRNA hypothesis has stirred the interest in the field of RNA biology, opening new mechanisms for interactions between RNAs [70, 71]. LncRNAs are sponges for miRNA, affecting gene expression, and participating in the ceRNA network [72]. As shown in Fig. 4, HIF1A-AS2 competitively modulates its downstream target genes via interacting with miRNAs and participating in development of human cancers. In GC, HIF1A-AS2 expression is up-regulated and promotes GC cell proliferation and metastasis by targeting the miR-429/PD-L1 axis [16]. HIF1A-AS2 promotes the expression of DNMT3A by binding to miR-129-5p and thereby contributing to the progression of CRC [22]. Zhong et al. found that SP1 binds to the 250 bp upstream promoter sequence of HIF1A-AS2 and promotes its transcription, and HIF1A-AS2 further promotes the expression of FOXC1 by engulfing miR-141-3p, thereby promoting the proliferation, metastasis and aerobic glycolysis of CRC cells [24]. Moreover, the carcinogenicity of CC is correlated to HIF1A-AS2/ miR-34b-5p/RDX axis [36]. HIF1A-AS2 acts as a ceRNA to inhibit the function of miR-146b-5p, thereby releasing the inhibition of the downstream target gene IL-6, resulting in the increased expression of IL-6 and STAT3, and finally promoting the proliferation, migration, invasion and the development of osimertinib resistance of LUAD cells [43]. Additionally, HIF1A-AS2 promotes RCC progression by acting as a reservoir for miR-30a-5p to enhance SOX4 expression or selectively interacting with miR-130a-5p to enhance ERBB2 expression [46, 47]. A comprehensive diagram illustrating the involvement of lncRNA-miRNA-mRNA interactions in various types of human cancers utilizing HIF1A-AS2 Biological proteins and molecules interaction Other than acting as a molecular sponge for miRNAs to regulate the expression of miRNA downstream target genes, HIF1A-AS2 also regulates gene transcription and epigenetics by interacting with biomolecules (Fig. 5). In HNC, the expression of HIF1A-AS2 is up-regulated in hypoxic tumor cells and hypoxic tumor-derived exosomes, and HIF-1α directly binds to the regulatory region of HIF1A-AS2 to enhance its expression. However, HIF1A-AS2 enhances the autophagic degradation process of MHC-I by promoting the interaction between NBR1 protein and MHC-I, thereby reducing the stability of MHC-I on the surface of tumor cells, ultimately leading to impaired antigen presentation function and reduced CD8 + T cell infiltration, forming an immunosuppressive microenvironment to promote tumor immune escape [26]. Similarly, Yan et al. demonstrated that HIF1A-AS2 is involved in hypoxia-mediated imatinib resistance in GIST by activation of HIF1A-AS2 as a major transcriptional regulator of the hypoxia response and positive regulation of HIF1A-AS2 expression. High expression of HIF1A-AS2 inhibits imatinib-induced autophagy by inhibiting the expression of autophagy-related proteins phosphorylated Unc-51-like kinase 1 (p-ULK1), BECN1 (beclin 1), light chain 3I (LC3I) and light chain 3II (LC3II) and promoting the accumulation of autophagy substrate P62, which eventually leads to imatinib resistance in GIST cells [59]. More than 50% of BC patients have chemoresistance, which is the main obstacle to the treatment of BC. The expression of HIF1A-AS2 is increased in BC resistant cells, and HIF1A-AS2 inhibits the transcriptional activity of p53 family protein Bax by promoting the expression of high mobility group A1 (HMGA1), thus making BC cells resistant to cisplatin [31]. HIF1A-AS2 expression was significantly increased in CC tissues and HPV-positive CC cells. Mechanistically, HIF1A-AS2 is mediated by HPV16 E6 and regulates CC cell apoptosis through the P53/caspase9/caspase3 axis [34]. Transcriptome sequencing analysis revealed that MRPS23 was the downstream target protein of HIF1A-AS2. Rescue experiments further confirmed that HIF1A-AS2 affected the proliferation, migration, invasion and paclitaxel sensitivity of TNBC cells by regulating the expression of MRPS23 protein [55]. In hypoxic microenvironment, mesenchymal glioma stem cells specifically upregulate HIF1A-AS2, and HIF1A-AS2 directly binds RNA binding protein insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) and RNA helicase DHX9 to form a complex and jointly maintain the expression of downstream target gene HMGA1 [61]. HIF1A-AS2 regulates gene transcription and epigenetics by interacting with biomolecules Conclusion and future perspectives Overall, HIF1A-AS2 is better regarded as a context-dependent oncogenic lncRNA rather than a universal pan-cancer driver with identical functions across tumor types. Its biological effects vary according to cancer type, hypoxic status, driver mutations, viral infection background, and the immune microenvironment. Research shows that HIF1A-AS2 has a significant cancer promoting effect in cancers like GC, CRC, HNC, BLCA, CC, NSCLC, RCC, BC, GIST, OC, osteosarcoma and GBM by regulating cancer-related functions such as cell proliferation, migration, invasion, apoptosis, cell cycle regulation, drug resistance and EMT. Additionally, the expression levels of HIF1A-AS2 had clinic relevance in oncology, and were notably correlated with the pathologic grade of tumour, tumour size, lymph node metastasis, distant metastasis, DFS and OS. Mechanistically, the biological role of HIF1A-AS2 in cancer is quite complex, including the competitive binding of miRNA to regulate the downstream mRNA, and the interaction with other protein molecules. Moreover, levels of HIF1A-AS2 can distinguish the different between tumour and non-tumour tissue, and HIF1A-AS2 in serum can distinguish cancer patients from healthy people. Its specific tumour targeting and stability in plasma make it a promising biomarker for diagnosis, management and prognosis of cancers. While this work described the oncogenic function of HIF1A-AS2 and the associated molecular pathways in many human cancers, there is still a limited and incomplete understanding of HIF1A-AS2. Primarily, many existing studies focus on the levels of HIF1A-AS2 expression to correlate with clinicopathological characteristics, and the mechanisms of HIF1A-AS2, especially how HIF1A-AS2 cooperates with other molecules, still need further study. Another concern of the existing literature is the lack of corroboration from large clinical cohorts that comes from in vitro cell studies and animal experiments, which limits the translation of the findings into practice. Additionally, much of current work is focused on a single pathway. Hence, our understanding of the transcriptional aspects involved with HIF1A-AS2, the switch in structural change of subcellular localisation, the roles of other non-coding RNAs, and the entire network regulated by HIF1A-AS2 are still insufficient. Understanding the structural basis and the mechanism for the diverse functional roles of HIF1A-AS2 will help to fully comprehend its involvement in tumour biology and lay a theoretical basis for therapeutical strategies. Future research should focus on addressing current shortcomings and exploring new research directions. First, wide prospective clinical trials are necessary for the development of methods for detection and validation systems that can underpin the clinical meaning of HIF1A-AS2 as a biomarker for diagnosis and prognosis. Further, it is important to probe more deeply into the complex regulation made by HIF1A-AS2, in other non-coding RNAs, proteins and chromatin components to establish a comprehensive map of molecular regulatory mechanisms. Concurrently, we also require the development of specific inhibitors or design targeted therapeutic strategies against HIF1A-AS2, and pharmaco-dynamics and safety test. Advancing technologies such as artificial intelligence, machine learning algorithms, single-cell RNA sequencing, spatial transcriptomics, and proteomics will facilitate researchers to decipher the molecular landscape of HIF1A-AS2 and its dynamic network on tumor microenvironment. It is also important to explore the role of HIF1A-AS2 in regulating tumour immunity and investigate its effect on cancer treatment, especially in immune checkpoint blockade. In addition, given its potential role in immune regulation in head and neck squamous cell carcinoma, the combination of HIF1A-AS2-targeted approaches with immunotherapy deserves further investigation. Over the long term, HIF1A-AS2 will likely become a robust molecular biomarker and therapeutic target for precision medicine. Advances in gene editing technologies suggest that CRISPR/Cas9-based targeted knockout or regulation technologies will provide innovative therapeutic approaches to treat disease associated with HIF1A-AS2. Thus, personalized medicine strategies will need to be developed based on the accurate measurement of the expression pattern and function of HIF1A-AS2, so that precision treatment is truly individualized. And finding a simple, quick, and cheap method for detecting HIF1A-AS2 would be very important for clinical use. Collaborative work across different communities will also play a crucial part in this field, including the combination of basic science research, clinical translations, drug development and analysis by bioinformatics. In summary, HIF1A-AS2 is a significant oncogenic molecule that is crucial for initiation and progression of many types of human cancers, whose abnormal expression is closely related to unfavourable prognosis. By functioning through mechanisms such as ceRNA and other molecular mechanisms, HIF1A-AS2 regulates many important biological processes, including proliferation, invasion, migration, apoptosis and EMT. Although the studies listed above have shed some light on its essential function and mechanism, it is desirable to further develop the theoretical foundation and try to apply it clinically. With research method development and innovation of technology, HIF1A-AS2 can be a great tool in cancer diagnosis, treatment and prognosis evaluation in the future, with new ideas and hope for improving patient’s treatment. Author contributions Lei Luo, Juan Zhang and Tingting Yu: Conceptualization, Investigation, Writing-Original Draft and Review; Wenqian Tang and Jing Dong: Conceptualization, Writing-Review and Editing; Fan Yang: Supervision, Project Administration, and Manuscript Review. Funding Not applicable. Data availability No datasets were generated or analysed during the current study. Declarations Consent for publication Not applicable. Competing interests The authors declare no competing interests. Ethics approval and consent to participant Not applicable. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Lei Luo, Juan Zhang and Tingting Yu contributed equally to this work. References Associated Data Data Availability Statement No datasets were generated or analysed during the current study.